KR20160062200A - 종양성 질병들에 대한 치료 - Google Patents

종양성 질병들에 대한 치료 Download PDF

Info

Publication number
KR20160062200A
KR20160062200A KR1020167013067A KR20167013067A KR20160062200A KR 20160062200 A KR20160062200 A KR 20160062200A KR 1020167013067 A KR1020167013067 A KR 1020167013067A KR 20167013067 A KR20167013067 A KR 20167013067A KR 20160062200 A KR20160062200 A KR 20160062200A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
subject
treatment
quot
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167013067A
Other languages
English (en)
Korean (ko)
Inventor
존 시마드
Original Assignee
엑스바이오테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스바이오테크, 인크. filed Critical 엑스바이오테크, 인크.
Publication of KR20160062200A publication Critical patent/KR20160062200A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167013067A 2010-08-23 2011-08-23 종양성 질병들에 대한 치료 Ceased KR20160062200A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US37609710P 2010-08-23 2010-08-23
US61/376,097 2010-08-23
US40675910P 2010-10-26 2010-10-26
US61/406,759 2010-10-26
US41118310P 2010-11-08 2010-11-08
US61/411,183 2010-11-08
US201161480635P 2011-04-29 2011-04-29
US61/480,635 2011-04-29
PCT/US2011/048747 WO2012027324A2 (en) 2010-08-23 2011-08-23 Treatment for neoplastic diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137007024A Division KR20130108305A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026757A Division KR101910760B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Publications (1)

Publication Number Publication Date
KR20160062200A true KR20160062200A (ko) 2016-06-01

Family

ID=45594256

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020137007024A Ceased KR20130108305A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020187029749A Active KR102104296B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020207002089A Active KR102314003B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020167013067A Ceased KR20160062200A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020177026757A Active KR101910760B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020217032773A Ceased KR20210128021A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020247029350A Active KR102748255B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020137007024A Ceased KR20130108305A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020187029749A Active KR102104296B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020207002089A Active KR102314003B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020177026757A Active KR101910760B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020217032773A Ceased KR20210128021A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020247029350A Active KR102748255B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Country Status (17)

Country Link
US (3) US10294296B2 (enExample)
EP (3) EP3443985B1 (enExample)
JP (5) JP6241932B2 (enExample)
KR (7) KR20130108305A (enExample)
CN (3) CN107281488B (enExample)
AU (1) AU2011293554B9 (enExample)
DK (1) DK2608808T3 (enExample)
ES (2) ES2622482T3 (enExample)
IL (2) IL262856B (enExample)
MX (2) MX388939B (enExample)
NZ (1) NZ607472A (enExample)
PH (2) PH12013500316A1 (enExample)
PT (1) PT2608808T (enExample)
RU (2) RU2679119C2 (enExample)
SG (1) SG187853A1 (enExample)
WO (1) WO2012027324A2 (enExample)
ZA (1) ZA201301420B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
WO2016086044A1 (en) * 2014-11-24 2016-06-02 University Of Iowa Research Foundation Methods of treating cancer
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
CA2147151A1 (en) 1992-10-14 1994-04-28 Robert A. Snow Therapeutic and diagnostic imaging compositions and methods
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
PL202058B1 (pl) * 1999-08-09 2009-05-29 Merck Patent Gmbh Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
JPWO2002033094A1 (ja) 2000-10-19 2004-10-21 協和醗酵工業株式会社 Ｖｐｌｆの活性を阻害する抗体
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) * 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
JP4354280B2 (ja) 2002-03-01 2009-10-28 イミューノメディクス、インコーポレイテッド Ｒｓ７抗体
DK2213685T3 (en) 2002-09-06 2014-03-03 Medarex Llc Therapeutic anti-IL-1R1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
ATE482235T1 (de) 2003-06-13 2010-10-15 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
HUE025449T2 (en) * 2004-12-09 2016-04-28 Janssen Biotech Inc Immunoconjugates against Integrin, a method for their preparation and use
ATE470151T1 (de) 2005-08-02 2010-06-15 Xbiotech Inc Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
WO2007039552A1 (en) 2005-09-28 2007-04-12 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
AU2007238677B2 (en) 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
US20090191149A1 (en) 2006-05-15 2009-07-30 Xbiotech Inc. IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
SI2109623T1 (sl) * 2006-05-22 2012-05-31 Xbiotech Inc Zdravljenje raka z anti il protitelesi
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
CN102112154B (zh) 2008-05-30 2013-10-30 埃克斯生物科技公司 白细胞介素-1α抗体及使用方法
JP5976319B2 (ja) 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
KR20110110349A (ko) 2009-01-29 2011-10-06 아보트 러보러터리즈 Ｉｌ-1 결합 단백질
FR2945396A1 (fr) * 2009-05-07 2010-11-12 St Microelectronics Grenoble 2 Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce
MX2012004412A (es) 2009-10-15 2012-05-08 Abbott Lab Proteinas de union a il-1.
LT2575884T (lt) 2010-06-03 2018-09-25 Abbvie Biotechnology Ltd Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2694107T (pt) 2011-04-01 2018-11-27 Xbiotech Inc Tratamento para patologias dermatológicas
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
WO2014055541A1 (en) 2012-10-04 2014-04-10 Xbiotech, Inc. Treatment of psychiatric conditions
CN104684929A (zh) 2012-10-04 2015-06-03 埃克斯生物科技公司 治疗血管疾病及其并发症
EP2975054A4 (en) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
US9416172B2 (en) 2014-06-03 2016-08-16 Xbiotech, Inc. Compositions and methods for treating and preventing Staphylococcus aureus infections
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료

Also Published As

Publication number Publication date
PH12016500578A1 (en) 2017-03-06
CN107252484A (zh) 2017-10-17
PH12013500316A1 (en) 2016-09-02
EP2608808B1 (en) 2017-01-18
KR102748255B1 (ko) 2024-12-31
EP3075394B1 (en) 2018-11-28
MX388939B (es) 2025-03-20
EP3075394A1 (en) 2016-10-05
AU2011293554B9 (en) 2015-03-19
JP2021138750A (ja) 2021-09-16
US11932688B2 (en) 2024-03-19
EP2608808A4 (en) 2014-01-15
KR102104296B1 (ko) 2020-04-27
DK2608808T3 (en) 2017-04-24
JP2013536236A (ja) 2013-09-19
US20120045444A1 (en) 2012-02-23
RU2013110030A (ru) 2014-09-27
JP7316120B2 (ja) 2023-07-27
PT2608808T (pt) 2017-04-24
CN103153340A (zh) 2013-06-12
IL262856B (en) 2020-06-30
JP6241932B2 (ja) 2017-12-06
KR20200010609A (ko) 2020-01-30
JP6917681B2 (ja) 2021-08-11
CN107281488A (zh) 2017-10-24
RU2017112088A3 (enExample) 2019-01-24
SG187853A1 (en) 2013-03-28
ES2856723T3 (es) 2021-09-28
KR20170113687A (ko) 2017-10-12
US20230382989A1 (en) 2023-11-30
EP3443985B1 (en) 2020-12-16
KR20180116458A (ko) 2018-10-24
KR101910760B1 (ko) 2018-10-22
RU2679119C2 (ru) 2019-02-06
PH12016500578B1 (en) 2017-03-06
WO2012027324A2 (en) 2012-03-01
MX2013002160A (es) 2013-04-05
AU2011293554A1 (en) 2013-03-07
ES2622482T3 (es) 2017-07-06
AU2011293554B2 (en) 2015-02-26
KR20210128021A (ko) 2021-10-25
US20190127460A1 (en) 2019-05-02
MX342776B (es) 2016-10-12
CN107281488B (zh) 2021-02-09
US10294296B2 (en) 2019-05-21
JP2025166117A (ja) 2025-11-05
IL275350A (en) 2020-07-30
KR20240134401A (ko) 2024-09-09
RU2017112088A (ru) 2019-01-24
NZ607472A (en) 2014-09-26
KR20130108305A (ko) 2013-10-02
EP2608808A2 (en) 2013-07-03
IL275350B (en) 2021-07-29
KR102314003B1 (ko) 2021-10-19
JP2019194233A (ja) 2019-11-07
IL262856A (en) 2018-12-31
WO2012027324A3 (en) 2012-05-10
EP3443985A1 (en) 2019-02-20
JP2016175939A (ja) 2016-10-06
ZA201301420B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
JP7316120B2 (ja) 腫瘍性疾患のための治療
AU2015201228B2 (en) Treatment for neoplastic diseases
AU2015271978B2 (en) Treatment for neoplastic diseases
HK40002544A (en) Treatment for neoplastic diseases
HK40002544B (en) Treatment for neoplastic diseases
HK1229696B (en) Treatment for neoplastic diseases
HK1229696A1 (en) Treatment for neoplastic diseases
HK1182635A (en) Treatment for neoplastic diseases

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160518

Application number text: 1020137007024

Filing date: 20130319

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161020

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170425

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161020

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170425

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20161220

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170824

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170724

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170425

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161220

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161020

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170922

Application number text: 1020137007024

Filing date: 20130319